Leerink Partners Remains Bullish on Biogen (BIIB) Following 3Q Earnings Results
Tweet Send to a Friend
Leerink Partners reiterated an Outperform rating and $425.00 price target on Biogen (NASDAQ: BIIB) following the company's 3Q15 earnings results ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
